TY - JOUR
T1 - Interactions between the amino‐terminal domain of p56lck and cytoplasmic domains of CD4 and CD8α in yeast
AU - Campbell, Kerry S.
AU - Buder, Annie
AU - Deuschle, Ulrich
PY - 1995/8
Y1 - 1995/8
N2 - The interactions between CD4 or CD8 and p56lck were tested using the twohybrid protein interaction system in yeast. Plasmid constructs were created which fuse the cytoplasmic domains of either CD4 or CD8α to the DNA‐binding protein LexA, and the unique amino‐terminal domain of p56lck fused to a transcriptional activation domain. These constructs were transfected into yeast bearing lacZ and LEU2 reporter genes controlled by upstream LexA operator sequences. Yeast transfectants bearing either CD4 or CD8α hybrid proteins in combination with the amino terminal p56lck hybrid protein exhibited increased β‐galactosidase activity and growth on leucine‐deficient medium, indicating interactions between these protein domains. Quantitation of reporter activation indicated that the interaction of p56lck with CD8α is at least 18‐fold weaker than the interaction with CD4 in this assay. This reduced interactive capacity is apparently not due to competition by CD8α interacting with itself, since homotypic or heterotypic interactions between CD8α and/or CD4 could not be detected. Truncation and point mutants demonstrated that the interactions of p56lck with CD4 or CD8α were dependent on the integrity of a pair of cysteines on each protein. The results indicate that these interactions do not require any additional proteins. Additionally, expression of the entire p56lck molecule as a hybrid with LexA resulted in dramatic reduction in the growth of yeast. Though the two‐hybrid system is a powerful tool for examining protein interactions, this result indicates potential limitations in studying full‐length src family tyrosine kinases in yeast.
AB - The interactions between CD4 or CD8 and p56lck were tested using the twohybrid protein interaction system in yeast. Plasmid constructs were created which fuse the cytoplasmic domains of either CD4 or CD8α to the DNA‐binding protein LexA, and the unique amino‐terminal domain of p56lck fused to a transcriptional activation domain. These constructs were transfected into yeast bearing lacZ and LEU2 reporter genes controlled by upstream LexA operator sequences. Yeast transfectants bearing either CD4 or CD8α hybrid proteins in combination with the amino terminal p56lck hybrid protein exhibited increased β‐galactosidase activity and growth on leucine‐deficient medium, indicating interactions between these protein domains. Quantitation of reporter activation indicated that the interaction of p56lck with CD8α is at least 18‐fold weaker than the interaction with CD4 in this assay. This reduced interactive capacity is apparently not due to competition by CD8α interacting with itself, since homotypic or heterotypic interactions between CD8α and/or CD4 could not be detected. Truncation and point mutants demonstrated that the interactions of p56lck with CD4 or CD8α were dependent on the integrity of a pair of cysteines on each protein. The results indicate that these interactions do not require any additional proteins. Additionally, expression of the entire p56lck molecule as a hybrid with LexA resulted in dramatic reduction in the growth of yeast. Though the two‐hybrid system is a powerful tool for examining protein interactions, this result indicates potential limitations in studying full‐length src family tyrosine kinases in yeast.
KW - Amino Acid Sequence
KW - CD4 Antigens/metabolism
KW - CD8 Antigens/metabolism
KW - Cell Division
KW - Genes, Reporter/genetics
KW - Lymphocyte Specific Protein Tyrosine Kinase p56(lck)
KW - Molecular Sequence Data
KW - Protein-Tyrosine Kinases/metabolism
KW - Saccharomyces cerevisiae
KW - beta-Galactosidase/analysis
UR - http://www.scopus.com/inward/record.url?scp=0029131489&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:A1995RQ08000041&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1002/eji.1830250842
DO - 10.1002/eji.1830250842
M3 - Article
C2 - 7664803
SN - 0014-2980
VL - 25
SP - 2408
EP - 2412
JO - European Journal of Immunology
JF - European Journal of Immunology
IS - 8
ER -